How Analyst Views on Royalty Pharma Are Shifting With Recent Acquisition and Growth Moves [Yahoo! Finance]
Royalty Pharma plc - Class A Ordinary Shares (RPRX)
US:NASDAQ Investor Relations:
ir.reprosrx.com/investor-relations
Company Research
Source: Yahoo! Finance
This indicates a modestly more optimistic outlook in the wake of its acquisition agreement with XenoTherapeutics. Analysts attribute this upward revision largely to stronger expectations for the company's revenue growth, now projected to climb from 17.6% to 18.5%. Stay tuned to discover how investors can track these evolving forecasts and stay informed on the shifting narrative surrounding Royalty Pharma. Stay updated as the Fair Value for Royalty Pharma shifts by adding it to your watchlist or portfolio . Alternatively, explore our Community to discover new perspectives on Royalty Pharma. What Wall Street Has Been Saying Analyst opinion on Royalty Pharma has evolved following the announcement of its acquisition by XenoTherapeutics. Insights from TD Cowen provide a window into current sentiment on the stock's outlook and valuation. ?? Bullish Takeaways TD Cowen notes minimal risk to the XenoTherapeutics deal closing. This may offer downside protection for current shareholder
Show less
Read more
Impact Snapshot
Event Time:
RPRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RPRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RPRX alerts
High impacting Royalty Pharma plc - Class A Ordinary Shares news events
Weekly update
A roundup of the hottest topics
RPRX
News
- Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Funding AgreementGlobeNewswire
- Royalty Pharma plc (RPRX) Presents at Evercore 8th Annual Healthcare Conference Transcript [Seeking Alpha]Seeking Alpha
- Royalty Pharma (NASDAQ:RPRX) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=RPRX&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street ZMarketBeat
- Royalty Pharma to Present at Upcoming Investor Conferences [Yahoo! Finance]Yahoo! Finance
- Royalty Pharma to Present at Upcoming Investor ConferencesGlobeNewswire
RPRX
Sec Filings
- 12/3/25 - Form 4
- 12/3/25 - Form 4
- 12/1/25 - Form 144
- RPRX's page on the SEC website